|
Nov 11, 2026
|
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
|
|
|
Nov 09, 2026
|
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
|
|
|
Nov 06, 2026
|
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
|
|
|
Nov 05, 2026
|
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
|
|
|
Sep 10, 2026
|
Nkarta to Participate in September Investor Conferences
|
|
|
Sep 08, 2026
|
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
|
|
|
Aug 10, 2026
|
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
|
|
|
May 12, 2026
|
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
|
|
|
Apr 15, 2026
|
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
|
|
|
Apr 09, 2026
|
Nkarta to Participate in Needham Virtual Healthcare Conference
|
|
